Dexmedetomidine use in critical care

AACN Advanced Critical Care

Volumn 19, Issue 2, 2008, Pages 113-120

  Lam, Simon W ^a   Alexander, Earnest ^b  

^a NewYork Presbyterian Hospital   (United States)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMEDETOMIDINE;

ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; HUMAN;

ADRENERGIC ALPHA-AGONISTS; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; DEXMEDETOMIDINE; HUMANS;

EID: 48549102192     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/01.AACN.0000318109.06073.35     Document Type: Article

References (18)

1. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59(2):263-268, discussion 269-270.
2. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000;4(5):302-308.
3. Paris A, Tonner PH. Dexmedetomidine in anaesthesia. Curr Opin Anaesthesiol. 2005;18(4):412-418.
4. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science. 1996;273(5276): 801-803.
5. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. Br J Anaesth. 2002;88(5):669-675.
6. Hospira. Precedex (Dexmedetomidine). Lake Forest, IL: Hospira.
7. Dasta JF, Kane-Gill SL, Durtschi AJ. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. Ann Pharmacother. 2004;38(7/8):1130-1135.
8. Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med. 2003;29(2):201-207.
9. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188-2196.
10. Penttila J, Helminen A, Anttila M, Hinkka S, Scheinin H. Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Can J Physiol Pharmacol. 2004;82(5):359-362.
11. Ingersoll-Weng E, Manecke GR Jr, Thistlethwaite PA. Dexmedetomidine and cardiac arrest. Anesthesiology. 2004;100(3):738-739.
12. Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med. 2003;18(1):29-41.
13. Bachand R, Scholz J, Pinaud M, et al. The effects of dexmedetomidine in patients in the intensive care setting [abstract]. Intensive Care Med. 1999;25(suppl 1). Abstract 623.
14. Corbett SM, Rebuck JA, Greene CM, et al. Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation. Crit Care Med. 2005;33(5):940-945.
15. Elbaradie S, El Mahalawy FH, Solyman AH. Dexmedetomidine vs. propofol for short-term sedation of postoperative mechanically ventilated patients. J Egypt Natl Canc Inst. 2004;16(3):153-158.
16. Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery: Dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth. 2003;17(5):576-584.
17. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions. Br J Anaesth. 2001;87(5):684-690.
18. MacLaren R, Forrest LK, Kiser TH. Adjunctive dexmedetomidine therapy in the intensive care unit: A retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy. 2007;27(3):351-359.